Clinical Trial Update: Efficacy and Safety of Half Dose Alteplase Added to Heparine, in Patients With Moderate Pulmonary Embolism [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating half-dose alteplase added to heparin for moderate pulmonary embolism was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Embolism

Drugs mentioned

• Alteplase (alteplase)
• Heparin (unfractionated heparin)

Snippet

Sponsor: Azienda U.S.L. 1 di Massa e Carrara | Conditions: Pulmonary Embolism | Phase 3 | Status: WITHDRAWN